Rheumatoid Arthritis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Oryn Therapeutics, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, P

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rheumatoid Arthritis pipeline constitutes key companies continuously working towards developing Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Rheumatoid Arthritis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rheumatoid Arthritis Market.

The Rheumatoid Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rheumatoid Arthritis Pipeline Report: https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Rheumatoid Arthritis treatment therapies with a considerable amount of success over the years.
• Rheumatoid Arthritis companies working in the treatment market are Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, Taisho Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, GlaxoSmithKline, Aclaris Therapeutics, Modern Biosciences, Pfizer, Abivax, Abbvie, Bristol Myers Squibb, Kiniksa Pharmaceuticals, Oryn Therapeutics, 4D pharma plc., Landos Biopharma, Inc, Biozeus, and others, are developing therapies for the Rheumatoid Arthritis treatment
• Emerging Rheumatoid Arthritis therapies in the different phases of clinical trials are- SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, TS152, SM03, SHR0302, Otilimabb, ATI-450, MBS2320, PF-06651600, Obefazimod, ABBV-154, Branebrutinib, KPL-404, ORTD-1, MRx0006, LABP-69, BZ068, and others are expected to have a significant impact on the Rheumatoid Arthritis market in the coming years.
• In July 2022, Enosi Therapeutics, announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi's pipeline for Greater China. Enosi's Growth Factor Trap (EN-2000 Program) and TNFR1 Blocker (EN-1000 Program) were licensed as part of the partnership. Both programs have the potential to be used as cross-over drugs to treat cancer and autoimmune diseases. EN-2000 blocks inflammatory growth factors that drive cancer and rheumatoid arthritis while EN-1000 is a specific blocker of TNFR1, which Enosi believes may be useful in treating autoimmune disease.
• In February 2022, Biogen Inc. and Xbrane Biopharma AB announced that they have entered into a commercialization and license agreement to develop, manufacture, and commercialize Xcimzane™, a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol).
• In June 2022, Biogen Inc. and Bio-Thera Solutions, Ltd. presented positive Phase III data for BIIB800 (BAT1806), a biosimilar candidate referencing. The double-blind 52-week Phase III study randomized 621 patients with moderate to severe rheumatoid arthritis to receive either BIIB800 or the reference tocilizumab administered intravenously every 4 weeks at a dose of 8 mg/kg for the first 24 weeks. Data from the Phase III comparative clinical trial demonstrated that the investigational biosimilar candidate BIIB800 has equivalent efficacy and comparable safety and immunogenicity profile to the reference tocilizumab product.
• In June 2022, Revolo Biotherapeutics announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the Medicines and Healthcare products Regulatory Agency (MHRA) for its immune-resetting drug candidate, '1805, for the treatment of patients with moderately to severely active Rheumatoid Arthritis (RA). In February 2022, Revolo Biotherapeutics secured approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate two Phase II trials of its autoimmune disease drug candidate '1805. One of the trials will enrol moderate-to-severe active rheumatoid arthritis (RA) patients while another Phase II trial will have individuals with non-infectious, active, intermediate, or posterior uveitis or panuveitis.
• In December 2021, Theramex, entered into an agreement with Enzene Biosciences Limited to develop, register, and commercialize a biosimilar drug of Roche's reference medicine RoActemra (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialized from 2026 in Europe, the UK, Switzerland, and Australia.
• Obefazimod is an oral, first-in-class, small molecule being developed by Abivax in Phase II stage of development. Obefazimod generated promising pre-clinical data from collagen-induced arthritis animal models that were the basis for moving into the Phase IIa clinical trial in rheumatoid arthritis (RA).
• Zunsemetinib, an Investigational Oral MK2 Inhibitor, is being developed by Aclaris Therapeutics. Aclaris initiated study activities and began activating sites in December 2021 in the following two studies: ATI-450-RA-202: Phase IIb clinical trial of zunsemetinib in subjects with moderate to severe rheumatoid arthritis (RA). This is Aclaris' second Phase II clinical trial of zunsemetinib in subjects with moderate to severe RA and is primarily designed to assess the efficacy of multiple doses of zunsemetinib to aid in the selection of an optimal dose to progress in future development.
• In November 2021, SinoMab BioScience Limited announced that SM03 (Suciraslimab) Phase III clinical trial for rheumatoidarthritis (RA) has completed its targeted enrollment of 510 patients. Study results showed that Suciraslimab at a dose of600 mg with 4 and 6 infusions respectively, was both efficacious and well-tolerated - 10 - throughout the 24 weeks oftreatment when compared with the placebo group

Rheumatoid Arthritis Overview
Inflammatory arthritis and extraarticular involvement are two characteristics of rheumatoid arthritis (RA), an autoimmune illness of the joints. Multiple joints in both hands are frequently affected, and morning stiffness that may continue for many hours is usual.

Get a Free Sample PDF Report to know more about Rheumatoid Arthritis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Rheumatoid Arthritis Drugs Under Different Phases of Clinical Development Include:
• SBT-77-7101: Sonoma Biotherapeutics
• ON104: OncoOne
• ORTD 1: Oryn Therapeutics
• TJ003234: I-Mab Biopharma Co. Ltd.
• TCK-276: Teijin Pharma
• IRL-201805: Revolo Biotherapeutics
• LY3462817: Eli Lilly and Company
• Dekavil: Philogen
• AP1189: SynAct Pharma
• RC18: RemeGen
• SM03: SinoMab Bioscience

Rheumatoid Arthritis Pipeline Therapeutics Assessment
• Rheumatoid Arthritis Assessment by Product Type
• Rheumatoid Arthritis By Stage and Product Type
• Rheumatoid Arthritis Assessment by Route of Administration
• Rheumatoid Arthritis By Stage and Route of Administration
• Rheumatoid Arthritis Assessment by Molecule Type
• Rheumatoid Arthritis by Stage and Molecule Type

DelveInsight's Rheumatoid Arthritis Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Rheumatoid Arthritis product details are provided in the report. Download the Rheumatoid Arthritis pipeline report to learn more about the emerging Rheumatoid Arthritis therapies at:
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Rheumatoid Arthritis Therapeutics Market include:
Key companies developing therapies for Rheumatoid Arthritis are - Taisho Pharmaceutical, Zhejiang Hisun Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, RemeGen, GlaxoSmithKline, Modern Biosciences, Jiangsu Alphamab Biopharmaceuticals, Akros Pharma, Hanlim Pharm, Galapagos NV, Chong Kun Dang Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Aclaris Therapeutics, Abivax, AbbVie, Synact Pharma, Gilead sciences, Mesoblast, Rottapharm Biotech, Eli Lilly and Company, Kiniksa Pharmaceuticals, Abcentra, Cyxone, Yungjin Pharm. Co., Ltd. Taiho Pharmaceutical, Oscotec Inc., Pfizer, Janssen Research & Development, Cipher Pharmaceuticals Inc., KLUS Pharma Inc., Revolo Biotherapeutics, Lynk Pharmaceuticals, Beijing Baylx Biotech, Hope Biosciences, Kangstem Biotech, Celltex Therapeutics, I-Mab Biopharma Co. Ltd., Synermore Biologics Co., Ltd, Oryn Therapeutics, Arthrogen, Bayer, Amgen, Draconis Pharma, Biozeus, Landos Biopharma, Imcyse, Kymera Therapeutics, and others.

Rheumatoid Arthritis Pipeline Analysis:
The Rheumatoid Arthritis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rheumatoid Arthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rheumatoid Arthritis Treatment.
• Rheumatoid Arthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rheumatoid Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rheumatoid Arthritis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rheumatoid Arthritis drugs and therapies-
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rheumatoid Arthritis Pipeline Market Drivers
• Rising prevalence of arthritis and other joint disorders, rising combinational therapy of biologics for the treatment of RA, rich emerging pipeline, acceptance of biosimilars for treatment of RA are some of the important factors that are fueling the Rheumatoid Arthritis Market.

Rheumatoid Arthritis Pipeline Market Barriers
• However, high cost of biologics, low adherence to the drugs, lack of daily assessment of RA, delay in RA diagnosis and other factors are creating obstacles in the Rheumatoid Arthritis Market growth.

Scope of Rheumatoid Arthritis Pipeline Drug Insight
• Coverage: Global
• Key Rheumatoid Arthritis Companies: Sonoma Biotherapeutics, OncoOne, Oryn Therapeutics, I-Mab Biopharma Co. Ltd., Teijin Pharma, Revolo Biotherapeutics, Eli Lilly and Company, Philogen, SynAct Pharma, RemeGen, SinoMab Bioscience, Taisho Pharmaceutical, SinoMab, Jiangsu Hengrui Medicine, GlaxoSmithKline, Aclaris Therapeutics, Modern Biosciences, Pfizer, Abivax, Abbvie, Bristol Myers Squibb, Kiniksa Pharmaceuticals, Oryn Therapeutics, 4D pharma plc., Landos Biopharma, Inc, Biozeus, and others
• Key Rheumatoid Arthritis Therapies: SBT-77-7101, ON104, ORTD 1, TJ003234, TCK-276, IRL-201805, LY3462817, Dekavil, AP1189, RC18, SM03, TS152, SM03, SHR0302, Otilimabb, ATI-450, MBS2320, PF-06651600, Obefazimod, ABBV-154, Branebrutinib, KPL-404, ORTD-1, MRx0006, LABP-69, BZ068, and others
• Rheumatoid Arthritis Therapeutic Assessment: Rheumatoid Arthritis current marketed and Rheumatoid Arthritis emerging therapies
• Rheumatoid Arthritis Market Dynamics: Rheumatoid Arthritis market drivers and Rheumatoid Arthritis market barriers

Request for Sample PDF Report for Rheumatoid Arthritis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Rheumatoid Arthritis Report Introduction
2. Rheumatoid Arthritis Executive Summary
3. Rheumatoid Arthritis Overview
4. Rheumatoid Arthritis- Analytical Perspective In-depth Commercial Assessment
5. Rheumatoid Arthritis Pipeline Therapeutics
6. Rheumatoid Arthritis Late Stage Products (Phase II/III)
7. Rheumatoid Arthritis Mid Stage Products (Phase II)
8. Rheumatoid Arthritis Early Stage Products (Phase I)
9. Rheumatoid Arthritis Preclinical Stage Products
10. Rheumatoid Arthritis Therapeutics Assessment
11. Rheumatoid Arthritis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rheumatoid Arthritis Key Companies
14. Rheumatoid Arthritis Key Products
15. Rheumatoid Arthritis Unmet Needs
16 . Rheumatoid Arthritis Market Drivers and Barriers
17. Rheumatoid Arthritis Future Perspectives and Conclusion
18. Rheumatoid Arthritis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Rheumatoid Arthritis Market delveinsight.com/report-store/rheumatoid-arthritis-ra-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Rheumatoid Arthritis Epidemiology https://www.delveinsight.com/report-store/rheumatoid-arthritis-ra-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rheumatoid Arthritis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Chemotherapy Drugs Market https://www.delveinsight.com/report-store/chemotherapy-drugs-market
Chemotherapy Drugs Market By Drug Class (Alkylating Agents, Mitotic Inhibitors, Antimetabolites, Topoisomerase Inhibitors, And Others), By Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, And Others), By Route Of Administration (Oral And Parenteral), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increasing prevalence of different cancer types and increasing pharmaceutical trials for chemotherapy drugs.

Connected Drug Delivery Devices Market
https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market
Connected Drug Delivery Devices Market By Product (Connected Sensors [Connected Inhaler Sensors And Connectable Injection Sensors] And Integrated Connected Devices [Connected Inhaler Devices And Connected Injection Devices], By Technology (Bluetooth, Near-Field Communication (NFC), And Others), By End-User (Healthcare Providers And Homecare), And by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of chronic diseases such as diabetes and improving healthcare it infrastructure across the globe.

Gynecological Devices Market https://www.delveinsight.com/report-store/gynecological-devices-market
Gynecological Devices Market By Product (Gynecological Endoscopy Devices [Hysteroscope, Resectoscope, And Others), Endometrial Ablation Devices [Balloon Ablation Devices, Radiofrequency Ablation Devices, And Others], Contraceptive Devices [Temporary Birth Control And Permanent Birth Control], Diagnostic Imaging Systems, Fluid Management Systems, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of various gynecological ailments and increasing figure of surgical procedures across the globe.

Baby Wipes Market
https://www.delveinsight.com/report-store/baby-wipes-market
Baby Wipes Market By (Wet Wipes And Dry Wipes), By Distribution Channels (Supermarkets And Hypermarkets, E-Commerce, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2023-2028 owing to increased adoption of baby wipes for maintaining infant sanitation and increasing product development activities.

Probiotics Market
https://www.delveinsight.com/report-store/probiotics-market
Probiotics Market By Ingredient Type (Bacteria And Yeast), By Product Type (Functional Food And Beverages, Dietary Supplements, And Animal Feed), By Application (Human Nutrition And Animal Nutrition), By Distribution Channels (Supermarkets And Hypermarkets, Convenience Stores, And Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to rising demand for probiotics as a preventive healthcare and increasing product development activities.

Artificial Tears Market
https://www.delveinsight.com/report-store/artificial-tears-market
Artificial Tears Market By Product (Cellulose-Derived Tears, Glycerin-Derived Tears, Polyethylene Glycol And Propylene Glycol-Based Tears, And Others), By Delivery Method (Eye Drops And Eye Ointments), By Application (Dry Eye Disease, Allergies And Infections, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence dry eyes syndrome and increasing availability of over the counter (otc) artificial tears.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.